Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a type of blood cancer called systemic non-Hodgkin lymphoma (confirmed by a laboratory tissue test), and whose cancer either carries a high risk of spreading to the brain (based on a scoring system called CNS IPI, scoring 4–6), or involves the kidneys, adrenal glands, testicles, breasts, or is a specific skin-based type called primary cutaneous DLBCL, leg type
• People whose cancer responded to initial treatment, either completely (full remission) or partially (partial remission)
• People aged 18 to 70 years
• People whose kidneys, liver, lungs, blood counts, and heart are functioning well enough to meet specific medical thresholds (the trial site will assess this through blood tests, heart scans, and other checks)
• Women who could become pregnant must have a negative pregnancy test before joining, and all participants must use effective contraception throughout the study treatment period
• People who are able to follow the study plan as assessed by the trial doctors
• People who give their written consent to participate voluntarily and understand what the study involves; for participants who cannot read or write, a literate family member must be present and provide written consent on their behalf

Who may not be able to join:

• People whose lymphoma started in the brain or spinal cord (called primary central nervous system lymphoma)
• People who have another active cancer, a life-threatening illness, or who were treated for a previous cancer less than 2 years ago
• People with moderate or severe mouth sores (grade 2 or higher mucositis)
• People with heart failure, poorly controlled high blood pressure, or unstable heart disease
• People with an infection that is not under control
• People whose disease continues to progress without being controlled during the study
• People who have previously received a stem cell transplant from a donor (allogeneic transplant)
• People with any other condition that the trial doctors believe could interfere with the safety or effectiveness of the study
• People with a serious allergy to any of the medicines used in the study
• Women who are pregnant or breastfeeding
• People who are unwilling to use contraception from the time of signing consent until 6 months after finishing study treatment
• People who are unlikely to be able to complete all required visits and follow-up appointments, as judged by the trial doctors

Important: Always verify eligibility with the trial site directly before applying.